NCT03912064 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 25
- units
- Participants
- groups
- description
- 1 mg/kg of Ipilimumab will be administered intravenously over 90 ± 10 minutes after the DLI product observation period is completed, and dosing will continue in 3-week intervals for 4 cycles, unless unacceptable toxicity or symptomatic disease progression occurs.
- id
- BG000
- title
- Dose Level: 0
- description
- 3 mg/kg of Ipilimumab will be administered intravenously over 90 ± 10 minutes after the DLI product observation period is completed, and dosing will continue in 3-week intervals for 4 cycles, unless unacceptable toxicity or symptomatic disease progression occurs.
- id
- BG001
- title
- Dose Level: 1
- description
- 10 mg/kg of Ipilimumab will be administered intravenously over 90 ± 10 minutes after the DLI product observation period is completed, and dosing will continue in 3-week intervals for 4 cycles, unless unacceptable toxicity or symptomatic disease progression occurs.
- id
- BG002
- title
- Dose Level: 2
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 25
- upper Limit
- 72
- value
- 65
- group Id
- BG001
- lower Limit
- 20
- upper Limit
- 77
- value
- 57.5
- group Id
- BG002
- lower Limit
- 68
- upper Limit
- 68
- value
- 68
- group Id
- BG003
- lower Limit
- 20
- upper Limit
- 77
- value
- 65
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 11
- title
- Female
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 14
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 22
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Black/African American
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Unknown/Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 25
- units
- Participants
- groups
- description
- 1 mg/kg of Ipilimumab will be administered intravenously over 90 ± 10 minutes after the DLI product observation period is completed, and dosing will continue in 3-week intervals for 4 cycles, unless unacceptable toxicity or symptomatic disease progression occurs.
- id
- BG000
- title
- Dose Level: 0
- description
- 3 mg/kg of Ipilimumab will be administered intravenously over 90 ± 10 minutes after the DLI product observation period is completed, and dosing will continue in 3-week intervals for 4 cycles, unless unacceptable toxicity or symptomatic disease progression occurs.
- id
- BG001
- title
- Dose Level: 1
- description
- 10 mg/kg of Ipilimumab will be administered intravenously over 90 ± 10 minutes after the DLI product observation period is completed, and dosing will continue in 3-week intervals for 4 cycles, unless unacceptable toxicity or symptomatic disease progression occurs.
- id
- BG002
- title
- Dose Level: 2
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 25
- upper Limit
- 72
- value
- 65
- group Id
- BG001
- lower Limit
- 20
- upper Limit
- 77
- value
- 57.5
- group Id
- BG002
- lower Limit
- 68
- upper Limit
- 68
- value
- 68
- group Id
- BG003
- lower Limit
- 20
- upper Limit
- 77
- value
- 65
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 11
- title
- Female
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 14
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 22
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Black/African American
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Unknown/Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle